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S U M M A R Y
Objectives: To evaluate reported cases of central nervous system (CNS) infections due to vancomycin-
resistant enterococci (VRE) and describe the data necessary to better understand clinical characteristics
of this rare disease process.
Methods: We report two cases of VRE CNS infection and review 36 cases reported in the literature.
Results: Eighty-two percent (31/38) of cases were due to Enterococcus faecium. The median length of stay
prior to diagnosis was 14 days (interquartile range 9–33). Fifty-eight percent (22/38) of cases had
signiﬁcant underlying non-malignant CNS disease processes and 63% (24/38) had CNS devices in situ.
Forty percent (15/38) of patients had other positive culture sites. Ninety-two percent (35/38) of patients
experienced microbiological cure and 74% (28/38) experienced clinical and microbiological cure
following a variety of antimicrobial therapies. Seventy-four percent (14/19) of patients who experienced
clinical/microbiological cure with CNS devices had them either removed or replaced. Eighteen percent
(7/38) died from VRE CNS infections.
Conclusions: VRE CNS infections are uncommon nosocomial infections that most commonly affect
patients with underlying CNS disease processes. The vast majority of cases are due to E. faecium, and
many cases involve multiple positive culture sites. Optimal antimicrobial therapy remains undeﬁned,
but should be coupled with removal or replacement of indwelling CNS devices.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The enterococci have emerged in recent years as signiﬁcant
pathogens causing infections in both nosocomial and community
settings. Once thought to be relatively harmless commensals,
they are now the third leading cause of nosocomial bloodstream
infections.1 Antimicrobial resistance in enterococci has been
reported increasingly, with the ﬁrst case of vancomycin
resistance documented in 1988.2 Vancomycin resistance occurs
in 60% of Enterococcus faecium isolates causing nosocomial
bloodstream infections.1 Enterococcal meningitis is relatively
uncommon, accounting for only 0.3% to 4% of cases of bacterial
meningitis.3 Vancomycin-resistant enterococci (VRE) as a cause* Corresponding author. Tel.: +1 804 301 4953; fax: +1 804 828 2125.
E-mail address: wangjs2@vcu.edu (J.S. Wang).
http://dx.doi.org/10.1016/j.ijid.2014.01.009
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).of central nervous system (CNS) infection is extremely rare, and
has been described in the literature primarily as individual case
reports and small case series. Herein, we report two cases of CNS
infections due to VRE and review 36 cases of VRE CNS infections
reported in the literature. To our knowledge, we provide the
most comprehensive review of VRE CNS infections to date,
including underlying comorbid conditions, clinical features,
cerebrospinal ﬂuid (CSF) characteristics, treatment regimens,
and outcomes.
2. Case reports
2.1. Case 1
A 19-year-old woman with acute myelogenous leukemia was
admitted for umbilical cord blood transplantation. Her post-transplant
course was complicated by viral infections (cytomegalovirus (CMV),ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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post-transplant she developed fever, and two sets of blood
cultures yielded Enterococcus spp resistant to vancomycin
(minimum inhibitory concentration (MIC) 32 mg/ml) and
ampicillin (MIC 16 mg/ml), and susceptible to quinupristin–
dalfopristin (MIC 0.5 mg/ml), linezolid (MIC 2 mg/ml), and
high-level gentamicin (MIC <500 mg/ml). Daptomycin (6 mg/kg
intravenous (IV) daily) and gentamicin (1 mg/kg IV every 8 h)
were started and her Hickman catheter was removed. Eight days
later she remained bacteremic and linezolid (600 mg per os (PO)
every 12 h) was added. Subsequent blood cultures revealed that
the VRE isolate had become resistant to linezolid (MIC 8 mg/ml),
therefore it was stopped and rifampin (300 mg PO every 8 h)
was added.
She remained bacteremic and 23 days after starting anti-
microbials became unresponsive and demonstrated left gaze
deviation and tonic/clonic movements of the extremities. A head
computed tomography (CT) scan revealed hydrocephalus and an
external ventricular drain was placed. CSF cultures obtained at the
time of ventriculostomy placement yielded VRE, with a suscepti-
bility proﬁle consistent with the previous blood isolate. At this
time, the VRE treatment regimen was changed to chloramphenicol
(500 mg IV every 6 h), daptomycin (increased to 8 mg/kg IV daily),
gentamicin (1 mg/kg IV every 8 h), and rifampin (300 mg PO every
8 h). On day 27, gentamicin was discontinued due to decreased
urine output. After multiple CSF cultures revealed vancomycin-
susceptible enterococci and the presence of multiple enterococcal
species could not be excluded, vancomycin (15 mg intraventricular
(VT) daily) and gentamicin (4 mg VT daily) were added to her
therapy (on days 29 and 30, respectively). On day 35, all cultures
(blood and CSF) were vancomycin-resistant; consequently VT
vancomycin was discontinued and replaced with quinupristin–
dalfopristin (2 mg VT daily). Intraventricular quinupristin–
dalfopristin was discontinued after 6 days of therapy and changed
to daptomycin (5 mg VT every 48 h) since CSF cultures continued
to be positive for VRE. On day 40 and day 52, blood and CSF cultures,
respectively, were ﬁnally sterile. Transthoracic echocardiography
did not reveal any evidence of endocarditis. The patient was treated
for an additional 6 weeks of antibiotic therapy, which consisted of
daptomycin (IV), chloramphenicol (IV), rifampin (PO), daptomycin
(VT), and gentamicin.
The patient was discharged 101 days following transplant;
however, she was readmitted on day 133 post-transplant for
treatment of lower gastrointestinal bleeding, CMV viremia, and
Streptococcus viridans bacteremia. She subsequently developed
altered mental status, left-sided weakness, lethargy and headache,
and status epilepticus requiring pentobarbital coma. However, the
VRE infection did not recur after completion of therapy,
demonstrated by negative blood and CSF cultures. On post-
transplant day 162, the patient was transitioned to palliative care
and died.
2.2. Case 2
A 51-year-old woman with systemic sclerosis status post
chemotherapy, total body irradiation, cyclophosphamide, equine
anti-thymocyte globulin, autologous stem cell transplant, and
subsequent myelodysplastic syndrome was transferred from an
outside hospital after treatment with azacitidine led to febrile
pancytopenia and bilateral pulmonary inﬁltrates. Culture from
bronchoscopy obtained prior to transfer revealed one colony of
Enterococcus spp (no susceptibility testing was performed). The
patient was treated with ceftriaxone and vancomycin at the
outside hospital, but was subsequently switched to daptomycin
6 mg/kg IV daily and cefepime upon transfer. The patient
developed VRE bacteremia and a transthoracic echocardiogramnoted vegetations on the aortic and mitral valves. Gentamicin
1 mg/kg IV every 8 h was added. The patient later developed
confusion and a CT scan of the head revealed non-communicating
hydrocephalus. Head magnetic resonance angiography and ve-
nography did not show any evidence of cerebral aneurysm. CSF
cultures were negative. The patient’s altered mental status
improved after lumbar puncture but she again developed
confusion, with a subsequent head CT revealing a subarachnoid
hemorrhage. A repeat lumbar puncture was performed and VRE
was isolated from the CSF. Chloramphenicol 1000 mg IV every 6 h
and rifampin 300 mg IV every 8 h were added to the antibiotic
regimen. However, within 3 days the patient developed acute
respiratory failure and subsequently died.
3. Methods
A literature review of VRE CNS infections was performed using
the Medline/PubMed database. Multiple searches were performed,
all of which were limited to English-language articles published
from 1988 (the year in which vancomycin resistance in an
enterococcal isolate was ﬁrst reported) through June 2013. Search
terms used were vancomycin-resistant Enterococcus meningitis,
vancomycin-resistant enterococcal meningitis, glycopeptide-re-
sistant Enterococcus meningitis, vancomycin-resistant Enterococ-
cus ventriculitis, and vancomycin-resistant Enterococcus brain
abscess. This search strategy yielded a total of 126 articles. All
relevant articles were reviewed as were the references from
pertinent articles to identify additional reports.
CNS infection was deﬁned as the isolation of organisms from at
least one CSF culture associated with clinical manifestations of
meningitis or ventriculitis and classical CSF ﬁndings including
pleocytosis (white blood cell (WBC) count 10  106/l), increased
protein concentration (>45 mg/dl), or decreased glucose level (<
40 mg/dl). If the authors claimed a case of meningitis or
ventriculitis and did not report the CSF parameters then the case
was included. Vancomycin resistance was deﬁned as a vancomycin
MIC 32 mg/ml. If the authors claimed that the isolate was
resistant to vancomycin without reporting the MIC, the case was
included; however, if the reported MIC was <32 mg/ml, the case
was excluded. Neutropenia was deﬁned as an absolute neutrophil
count <1  109/l. Microbiological cure was deﬁned as a negative
CSF culture and clinical cure was deﬁned as survival with clinical
resolution of infection. Articles that presented aggregate patient
data (e.g., clinical trials in which data on individual patients were
not reported) were excluded. Cases reporting polymicrobial
infections were also excluded.
Eleven cases were excluded from our analysis. In ﬁve cases the
infecting organisms had a vancomycin MIC of <32 mg/ml;4–8 in
four cases the patient had polymicrobial CNS infection.9–12 One
case was presented in the setting of aggregate data with no speciﬁc
case details presented and was therefore excluded.3 One case was
from an abstract reference that was not obtainable for review and
was therefore excluded.13 Our analysis yielded 36 cases of VRE CNS
infections. Combined with our two additional cases, a total of 38
cases are presented herein.
Data were analyzed using JMP Pro version 10.0.0 (SAS Institute,
Cary, NC, USA). Normality of data was assessed by visual inspection
of the normal quantile plot. Normally distributed data were
described using the mean (standard deviation (SD)), while non-
normally distributed data were described with the median
(interquartile range (IQR)).
4. Results
Case details are shown in Table 1.14–43 The ages of affected
individuals ranged from neonate (<4 weeks old) to 82 years old,
Table 1
Characteristics of patients with central nervous system (CNS) infections due to vancomycin-resistant enterococci (VRE)
[Ref.] year Age, sex Underlying
condition(s)
Clinical features Treatment CNS device and
management
Outcome
[14] 1994 6 years, M Seizure disorder s/p
brain grid placement
Fever, AMS, headache,
meningeal signs,
seizures
Am IV  7 days; Cm
and Rf  14 days; Tc
IT  14 days
Brain grid removed,
lumbar drain placed
then removed at a later
date
Clinical and microbiological
cure
[15] 1995 8 months, F Intraventricular bleed,
shunt infections
Fever, AMS Ch IV and Gn IV and VT;
Q/D IV and Q/D VT  28
days
Shunt removed,
Ommaya placed,
intraventricular lavage
Clinical and microbiological
cure
[16] 1996 71 years, F Ethmoid sinus invasive
aspergillosis
NR Q/D IV  22 days NA Death, microbiological cure
[17] 1998 23 years, M Spina biﬁda, VPS
infection, replaced
with catheter
NR Ch IV  2 months; Q/D
VT  5 doses; Q/D
IV  10 days
Ventricular catheter
removed then replaced
several days later
Death, microbiological cure
[18] 1998 42 years, F CML s/p induction
chemotherapy and
BMT
Fever, AMS, headache,
seizures
Ch IV  10 days; Q/
D  1 week
NA Death, no microbiological
cure
[19] 1998 Neonate,
NR
TAPVR s/p repair,
necrotizing
enterocolitis
Fever Ch  13 days; Tc; Q/
D  13 days
NA Clinical and microbiological
cure
[20] 2000 50 years, F SAH s/p embolization,
hydrocephalus s/p EVD
Seizures Do PO; Q/D IV  4 days;
Q/D IT; Q/D VT; Lz IV
EVD replaced then
removed, lumbar drain
placed, then ﬁnal EVD
placed
Death, microbiological cure
[21] 2001 69 years, M DM, HTN, CAD, AHA,
Strongyloides infection
Fever, AMS Ch  6 days; Lz IV  28
days
NA Clinical and microbiological
cure
[22] 2001 35 years, M AVM, ventriculostomy,
craniectomy,
pneumonia
Fever Ox and Ch IV; Lz IV  4
weeks
New EVD placed, after
completing Lz VPS
placed
Clinical and microbiological
cure
[23] 2001 62 years, M Renal cancer with CNS
metastasis, EVD to VPS,
MI, pneumonia
Fever, AMS Am  2 days; Lz IV  3
weeks; Gn IV  7 days;
Gn VT
VPS not removed Clinical cure then died from
cancer, microbiological cure
[24] 2002 7 months, M Pulmonary HTN,
hydrocephalus s/p VPS
Fever, seizures Lz  21 days VPS removed then
replaced after 10 days
of Lz
Clinical and microbiological
cure
[25] 2003 67 years, M CNS lymphoma s/p
reservoir and
chemotherapy
Fever Q/D IV  9 weeks; Lz
IV  6 weeks; Q/D
VT  3 doses
Ommaya reservoir
replaced
Clinical and microbiological
cure
[26] 2004 38 years, M Oligoastrocytoma s/p
resection, abscess,
hydrocephalus s/p EVD
Fever, seizures Ch IV  4 days Frontal abscess
resected, EVD replaced
Death, microbiological cure
[27] 2005 46 years, M SAH s/p craniotomy
and aneurysm clipping
Fever Ch IV  47 days; Ch
VT  35 days
EVD placed on day 12
of Ch
Clinical and microbiological
cure
[28] 2006 69 years, M COPD on chronic
steroids, Klebsiella
pneumonia, UTI
Fever, AMS, meningeal
signs
Cf  2 days; Cp  2
days; Lz IV  2 weeks
NA Clinical and microbiological
cure
[29] 2006 7 months, M Hydrocephalus s/p
VPS, non-VRE
meningitis, EVD
Fever Ch, Rf, and Mp  9 days One week after
diagnosis EVD replaced
with Rf + Cl
impregnated EVD
Clinical and microbiological
cure
[30] 2006 51 years, F Cribriform plate defect
s/p lumbar drain
placement
Fever, headache Am and Rf  3 weeks Lumbar drain removed
on diagnosis, replaced
with lumboperitoneal
shunt
Clinical and microbiological
cure
[31] 2007 20 months, M Hydrocephalus s/p EVD
and VPS, cardiac arrest
Fever Lz IV  6 weeks New VPS placed after 4
weeks of Lz
Clinical and microbiological
cure
[32] 2008 73 years, M TBI with hemorrhage s/
p EVD then removal,
VPS
Fever, AMS, meningeal
signs
Lz IV and Rf PO  6
weeks; Da VT  4
weeks
VPS removed, EVD
placed then replaced
with Rf + Cl
impregnated EVD
Clinical and microbiological
cure
[33] 2008 64 years, M Melanoma with CNS
metastasis,
hydrocephalus s/p VPS,
EVD
NR Am IV  6 weeks; Lz
IV  10 days; St VT  10
days; St SBD  18 days
VPS removed, EVD
replaced then
removed, SBD placed
then removed
Clinical and microbiological
cure
[34] 2008 82 years, M COPD on chronic
steroids, pneumonia
Fever, AMS, headache,
meningeal signs
Am IV and Lz IV  3
weeks
NA Clinical and microbiological
cure
[35] 2008 17 months, M Hydrocephalus s/p
VPS, non-VRE
ventriculitis, EVD
NR Lz IV  18 days; Lz
PO  10 days
No removal, treated
through infection
Clinical and microbiological
cure
[36] 2010 53 days, F Sacrococcygeal
teratoma,
hydrocephalus s/p
reservoir
Fever, AMS Lz IV  54 days and Gn
IV  16 days; Ch
IV  40 days; Lz IV; Ch
VT  12 days
Rickham reservoir
removed and replaced
with bilateral EVDs
Clinical and microbiological
cure
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Table 1 (Continued )
[Ref.] year Age, sex Underlying
condition(s)
Clinical features Treatment CNS device and
management
Outcome
[37] 2010 58 years, M Trigeminal neuralgia s/
p craniotomy, subdural
hygroma s/p SBD
Fever, AMS Lz  10 days; Da IV  3
weeks; Gn  10 days
Unclear if SBD ever
replaced, lumbar drain
placed with negative
CSF cultures
Clinical and microbiological
cure
[37] 2010 78 years, M Lumbar surgeries with
spinal abscess, sepsis,
DIC
Fever, AMS Da IV  30 days; Gn
IV  9 days
NA Clinical and microbiological
cure
[37] 2010 68 years, M Hydrocephalus s/p
VPS, Klebsiella and
MRSA pneumonia
Fever, AMS Da IV and Lz IV  20
days
Revision and
externalization of VPS
on HD15
Clinical and microbiological
cure
[38] 2010 21 months, F Leukemia s/p SCT,
hydrocephalus s/p EVD
Fever, AMS Lz  4 weeks; Da IV  6
weeks; Da VT  12
days; Tg IV  2 weeks
EVD, no mention if
removed
Clinical and microbiological
cure
[39] 2010 31 weeks, F 4th of quadruplets, VRE
bacteremia
NR Lz  3 weeks NA Clinical and microbiological
cure
[40] 2012 48 years, F Schwannoma, s/p
retromastoid
craniotomy
Fever, AMS, headache Lz IV, Am, and Gn  1
month
NA Clinical cure then died from
hydrocephalus,
microbiological cure
[40] 2012 70 years, M Left chronic
suppurative otitis
media
Fever, AMS, headache NA NA Death, no microbiological
cure
[41] 2012 64 years, M Renal cell carcinoma,
DM, CVA, eosinophilic
pneumonia
AMS Lz IV  21 days; Da
VT  7 days
Right and left EVD
placed, right EVD
replaced
Clinical and microbiological
cure
[42] 2013 55 years, M AML s/p haploidentical
SCT
Fever, AMS, headache,
meningeal signs
Q/D IV and Da IV  4
weeks
NA Clinical cure then died from
sepsis, microbiological cure
[42] 2013 68 years, M EVD NR Lz PO  4 weeks EVD, no mention if
removed
Clinical outcome NR,
microbiological cure
[42] 2013 61 years, M Subdural hematoma s/
p drainage
NR Rf PO  6 days; Ch
IV  2 weeks; Lz PO  4
weeks
NA Clinical outcome NR,
microbiological cure
[42] 2013 72 years, F VPS NR Rf PO and Lz PO  4
weeks
VPS, no mention if
removed
Clinical outcome NR,
microbiological cure
[43] 2013 56 years, F Multiple myeloma s/p
SCT, thrombocytopenia
Fever, AMS Lz IV  3 weeks NA Clinical and microbiological
cure
Case 1 19 years, F AML s/p SCT, CMV,
seizure, hydrocephalus
s/p EVD
Fever, AMS Da IV; Lz PO; Gn IV; Rf
PO and Ch IV; Vm VT
and Gn VT; Q/D VT; Da
VT;  94 days
EVD not removed Clinical cure then died from
viremia, microbiological cure
Case 2 51 years, F Systemic sclerosis s/p
SCT, MDS,
hydrocephalus, SAH
Fever, AMS Da IV  10 days; Gn
IV  10 days; Ch IV  3
days; Rf IV  3 days
NA Death, no microbiological
cure
AHA, autoimmune hemolytic anemia; Am, ampicillin; AML, acute myelogenous leukemia; AMS, altered mental status; AVM, arteriovenous malformation; BMT, bone marrow
transplant; CAD, coronary artery disease; Cf, cefotaxime; Ch, chloramphenicol; Cm, clindamycin; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; COPD, chronic
obstructive pulmonary disease; Cp, cefepime; CSF, cerebrospinal ﬂuid; CVA, cerebrovascular accident; Da, daptomycin; DIC, disseminated intravascular coagulation; DM,
diabetes mellitus; Do, doxycycline; EVD, external ventricular device; F, female; Gn, gentamicin; HTN, hypertension; IT, intrathecal; IV, intravenous; Lz, linezolid; M, male;
MDS, myelodysplastic syndrome; MI, myocardial infarction; Mp, meropenem; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; NR, not reported; s/p,
status post; Ox, oxacillin; PO, per os; Q/D, quinupristin–dalfopristin; Rf, rifampin; RSAH, subarachnoid hemorrhage; SBD, surgical bed drain; SCT, stem cell transplant; St,
streptomycin; TAPVR, total anomalous pulmonary venous return; TBI, traumatic brain injury; Tc, teicoplanin; Tg, tigecycline; UTI, urinary tract infection; Vm, vancomycin;
VPS, ventriculoperitoneal shunt; VT, intraventricular.
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old (SD 28). With regards to gender, 66% (25/38) of the cases were
male, 32% (12/38) were female, and one was a gender unidentiﬁed
neonate. Children comprised 24% of the cases (9/38), while adults
made up the remaining 76%.
All patients had signiﬁcant comorbidities. Non-malignant CNS
disease processes were found in 22/38 (58%) patients. CNS devices
were present in 24/38 (63%) cases. Non-CNS infections, which we
deﬁne as any infection exclusive of meningitis and ventriculitis,
and include gastrointestinal infections, pneumonias, urinary tract
infections, skin and soft tissue infections, and bacteremias, were
found in 14/38 (37%) patients. Eleven of 38 (29%) patients had
underlying malignant processes (non-CNS), with 7/38 (18%) of
these processes being hematologic and 4/38 (11%) of these
processes being solid tumors. Three of 38 (8%) patients had
neutropenia. Six of 38 (16%) patients received hematopoietic stem
cell transplants. Five of 38 (13%) patients had CNS malignancies,
with two cases being primary disease and three cases being
metastatic disease. Pulmonary disease was found in 7/38 (18%)
patients.Hospitalization prior to developing VRE CNS infection was seen
in 29/38 (76%) cases. Patients were hospitalized from 7 to >80 days
prior to diagnosis. The median length of time hospitalized prior to
diagnosis was 14 days (IQR 9–33). Fever was reported in 28/28
(100%) patients and altered mental status was reported in 20/20
(100%) patients.
E. faecium was found in 31/38 (82%) cases. Enterococcus faecalis
and Enterococcus gallinarum were isolated in 2/38 (5%) cases each.
In 3/38 (8%) cases the species was not reported.
Fifteen of 38 patients (40%) had VRE isolated from sites other
than CSF. These included 10/15 (67%) cases involving positive
blood cultures, 3/15 (20%) cases involving positive brain tissue, 1/
15 (7%) cases involving a positive respiratory culture, and 1/15 (7%)
cases involving a positive urine culture. Gastrointestinal tract
colonization was found in 6/15 (40%) cases. Five patients had VRE-
positive cultures from multiple sites apart from the CSF.
At least some CSF parameters were reported in 28/38 (74%)
cases. The median CSF WBC count in the non-neutropenic patients
was 335  106/l (IQR 60–573). The median CSF WBC count in the
three neutropenic patients for which we have data was 27  106/l
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differential was 82% (SD 13). The mean glucose was 40 mg/dl (SD
31) and the mean protein was 240 mg/dl (SD 239). Gram stain
results were reported in 12 cases, with 10/12 (83%) cases reporting
Gram-positive cocci in various formations and 2/12 (17%) cases
reporting no bacteria on Gram stain.
Antibiotic treatment regimens ranged across a multitude of
options, with linezolid (24 patients), chloramphenicol (12
patients), quinupristin–dalfopristin (nine patients), and daptomy-
cin (nine patients) most often used. Gentamicin and rifampin
(eight patients each) were often used in combination with another
agent. Combination therapy was reported for 23/37 (62%) patients,
with 19/28 (68%) patients who had microbiological and clinical
cure having received combination therapy. The length of treatment
ranged from 3 days up to 8 weeks. The median duration of
treatment in patients with clinical and microbiological cure was 28
days (IQR 21–39). Intrathecal therapy was given in 2/37 (5%) cases,
involving teicoplanin and quinupristin–dalfopristin. Intraventric-
ular therapy was administered in 12/37 (32%) cases, involving
gentamicin, quinupristin–dalfopristin, chloramphenicol, dapto-
mycin, and streptomycin. Ten out of the 12 (83%) patients who
received intraventricular therapy experienced clinical and micro-
biological cure, while 2/12 (17%) patients who received intraven-
tricular therapy died from their VRE CNS infection. One patient
died prior to receiving any treatment. Adverse effects secondary to
antimicrobial therapy were reported in 17/38 (45%) cases and
ranged from anemia and thrombocytopenia to myalgias.
Of the 24 patients with CNS devices in situ, 18 (75%) were
removed or replaced during the course of hospitalization, three
(13%) were not removed, and in three other cases it was unclear
whether the CNS device was removed or not. Of the 24 cases with
CNS devices, 19 (79%) cases experienced microbiological and
clinical cure; of those, 14 (74%) had CNS devices replaced or
removed, three (16%) were not removed, and for two (11%) it was
unclear whether devices were removed or not. Out of the seven
patients who died from their VRE CNS infection, three (43%) had
CNS devices; of those three, none had their device removed.
Microbiological cure was obtained in 35/38 (92%) of the
patients. Clinical cure with microbiological cure was obtained in
28/38 (74%) cases. Death attributed to VRE CNS infection was
reported in 7/38 (18%) cases. Follow-up data were presented for
19/38 (50%) cases. The median length of follow up was 2.5 months
(IQR 1–8).
5. Discussion
Enterococcus species were originally thought of as harmless
commensal organisms that dwell in the human gastrointestinal
tract. Over the past few decades, they have arisen to become a
major cause of human disease, and can cause a wide variety of
infections, especially in immunocompromised patients. Over the
past few decades, the enterococci have gradually been acquiring
antimicrobial resistance; subsequently infections secondary to
VRE have been reported in increasing numbers. Despite this, CNS
infection due to VRE is still a rare phenomenon.
Patients with VRE CNS infection tend to be older. In our review,
the mean age of patients who developed VRE CNS infection was 44
years. VRE CNS infection is often associated with other sites of
enterococcal infection and colonization. Patients with VRE CNS
infections tend to have serious underlying diseases, including CNS
non-malignant disease, non-CNS infections, non-CNS malignan-
cies both hematologic and solid tumor, pulmonary disease,
cardiac disease, and CNS malignancies. The most prevalent
underlying condition was CNS non-malignant disease, followed
by non-CNS infections and non-CNS hematologic malignancies.
Clinical features typically associated with bacterial meningitis arefrequently found, with fever and altered mental status seen in all
patients.
We found E. faecium to be the enterococcal isolate in 31/38
(82%) cases of CNS infections due to VRE, while E. faecalis was
isolated in only 2/38 (5%) cases.
Abnormal CSF ﬁndings are common with VRE CNS infections.
Low-grade neutrophilic pleocytosis was typically present, along
with mild hypoglycorrhachia, and elevated protein concentration.
CSF Gram stain was typically positive and blood cultures were
often positive.
In regards to therapy and outcome, the duration of therapy in
patients successfully treated for VRE CNS infections was prolonged,
with a median of 28 days (IQR 21–39). CSF device removal occurred
in 18/24 (75%) patients with VRE CNS infections. Nearly 40%
received intraventricular or intrathecal antimicrobial therapy.
Our literature review carries a number of limitations. We only
included English language papers so relevant non-English lan-
guage cases may have been missed. Additionally, for many of the
cases that were reviewed, detailed case information was lacking.
Other potential limitations are publication and reporting bias.
Despite these potential limitations, we believe our review
positively contributes to the literature on these rare infections.
In conclusion, VRE CNS infections are rare nosocomial infec-
tions with only 38 cases reported in the literature over a 25-year
period. Patients uniformly have serious underlying conditions,
including non-malignant CNS disease, non-CNS infections, and
hematologic malignancies, with a majority of patients also having
indwelling CNS devices. Common clinical features include fever
and altered mental status. E. faecium is implicated in the majority
of VRE CNS infections. Concomitant positive blood cultures are
common, and CSF often reveals a pleocytosis, high protein, and
relatively low glucose. Optimal therapy remains undeﬁned, but
requires removal of indwelling CNS devices and the use of
bactericidal agents, and some cases may require direct instillation
of antimicrobial agents into the CSF. Despite these measures,
mortality from VRE CNS infections remains relatively high.
Conﬂict of interest: The authors have no potential conﬂicts of
interest to disclose. There are no sources of funding to disclose.
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